Total (N = 399) | CBD stone (N = 50) | No CBD stone (N = 349) | P value | ||
---|---|---|---|---|---|
Gender | Male, No. (%) | 175 (43.9%) | 16 (32%) | 159 (45.6%) | .07 |
Female, No. (%) | 224 (56.1%) | 34 (68%) | 190 (54.4%) | ||
Age (mean ± SD), years | 56 ± 19 | 47 ± 20 | 55 ± 18 | .01 | |
BMI (mean ± SD), kg/m2 | 28 ± 6 | 29 ± 6 | 28 ± 5 | .58 | |
Clinical presentation | Fever, No. (%) | 42 (10.5%) | 1 (2%) | 41 (11.7%) | .04 |
RUQ pain on admission, No. (%) | 355 (89%) | 42 (84%) | 313 (89.7%) | .23 | |
Associated cholecystitis, No. (%) | 325 (81.5%) | 33 (66%) | 292 (83.7%) | .003 | |
Admission LFTs (mean ± SD) | ASAT, IU/L | 167 ± 184 | 67 ± 146 | .001 | |
ALAT, IU/L | 166 ± 197 | 68 ± 121 | .001 | ||
PA, IU/L | 123 ± 97 | 81 ± 48 | .005 | ||
GGT, IU/L | 245 ± 276 | 94 ± 139 | .001 | ||
Total Bilirubin, μmol/L | 26 ± 17 | 20 ± 12 | .01 | ||
Conjugated Bilirubin, μmol/L | 18 ± 10 | 9 ± 7 | .002 | ||
Abnormal admission LFTs | ASAT (11–42 IU/L), No. (%) | 162 (40.6%) | 36 (72%) | 126 (36.1%) | < .001 |
ALAT (9–42 IU/L), No. (%) | 163 (40.9%) | 34 (68%) | 129 (37%) | < .001 | |
PA (30–125 IU/L), No. (%) | 75 (18.8%) | 14 (28%) | 61 (17.5%) | .07 | |
GGT (9–35 IU/L), No. (%) | 261 (65.4%) | 43 (86%) | 218 (62.5%) | .001 | |
Total Bilirubin (7–25 μmol/L), No. (%) | 97 (24.3%) | 20 (40%) | 77 (22.1%) | .006 | |
Conjugated Bilirubin (2–9 μmol/L), No. (%) | 319 (79.9%) | 45 (90%) | 274 (78.5%) | .06 |